Multicenter, randomized, open-label phase II study with two neoadjuvant treatment arms to evaluate the efficacy, safety and pharmacokinetics of GDC-9545 plus palbociclib compared to anastrozole plus palbociclib in postmenopausal women with cann

COMMERCIAL CLINICAL TRIAL